GENEWIZ Launches Expanded Next Generation Sequencing Services Including Quick-Turn Amplicon-EZ and Long-Read Amplicon Sequencing at ASHG

CLIA Sanger Sequencing also launched along with the announcement of a new PacBio® SMRT® Grant Program

SOUTH PLAINFIELD, New Jersey and ORLANDO, Florida, Oct. 17, 2017 /PRNewswire/ -- ASHG17, Booth #323 -- Leading global genomics service provider, GENEWIZ, launches CLIA Sanger sequencing and new NGS amplicon sequencing, at booth #323 during The American Society of Human Genomics (ASHG) Annual Meeting. ASHG is the largest gathering of human genetics professionals in the world and takes place this October 17-21, 2017 in Orlando.

"GENEWIZ scientists continually look for new ways to expand our services to better assist our customers in accelerating their scientific research. By expanding our industry-leading Sanger sequencing capabilities to include CLIA compliance, as well as offering two new levels of amplicon sequencing, we are doing just that!" says said Dr. Amy Liao, GENEWIZ Chief Executive Officer.

• Amplicon Sequencing
   
  GENEWIZ's new Amplicon-EZ service builds on the advantages of NGS-based screening and provides a cost-effective, fast, and interactive solution for researchers to sequence mixed PCR products. Amplicon-EZ is designed to allow every researcher to utilize next generation sequencing, regardless of sample number or expertise. Starting at only $50/sample, GENEWIZ provides easy-to-interpret results in as fast as three business days.
   
  The addition of Amplicon-EZ grows GENEWIZ's NGS amplicon sequencing services to three comprehensive options, including standard amplicon sequencing and contiguous long amplicon sequencing using Single Molecule, Real-Time long-read sequencing (also new to GENEWIZ).
   
• CLIA Sanger Sequencing
   
  GENEWIZ expands into clinical genomics testing with the launch of its CLIA Sanger Sequencing service which is CLIA-certified and CAP Accredited. Contributing to the advancements in clinical development, personalized medicine and molecular diagnostics, GENEWIZ now provides clinical Sanger sequencing to complement the work being done by its clients in both research and clinical environments. For more information contact [email protected].

In addition to these new services, GENEWIZ has teamed up once again with PacBio® on the newest SMRT® Grant Program. Launching at ASHG, this grant program is open to scientific researchers around the world who are looking to identify and characterize structural variants. The winner will receive long-read sequencing for up to three samples and 16 SMRT Cells, plus bioinformatic support. To enter visit web.genewiz.com/pacbio-sv-grant and fill out the entry form, including a 250-word proposal for how you would use PacBio long reads from the Sequel^® System to identify and characterize structural variants. Entries close at midnight (ET), December 11, 2017.

ABOUT GENEWIZ

GENEWIZ is a global leader in genomics services that enable research scientists within pharmaceutical, biotechnology, agriculture, environmental and clean energy, academic, and government institutions to advance their discoveries. Customers rely on our unique and proprietary genomics technologies and services, backed by our specialized experts in DNA sequencing, gene synthesis, molecular biology, high throughput sequencing, bioinformatics, and GLP regulatory-compliant services.

Headquartered in South Plainfield, NJ, GENEWIZ is privately-held with a network of laboratories in Boston, MA; Washington, D.C. Metro; Research Triangle Park, NC; San Diego, CA; Los Angeles, CA; San Francisco, CA; and Seattle, WA. International locations include Beijing, Suzhou, Tianjin, and Guangzhou, China; Takeley, United Kingdom; and Tokyo, Japan. For more information, visit www.genewiz.com, and connect with us on LinkedIn, Twitter, Facebook, YouTube, WeChat, and Weibo. More information is available at www.genewiz.com.